PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.83 +5.29%

+$0.09 today

Market cap
$265.27M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 3.39M

Average 1.37M

PEPG Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

PepGen Inc.NASDAQ: PEPG

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 69.09M shares rose 111.5% year over year, ahead of the +35.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 63.6% from the prior quarter. Over 3 fiscal years it compounded at +39.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +111.5% holds above the trailing-twelve-month pace of +35.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
69.09M+63.6% QoQ
Last fiscal yearDec 2025
42.22M+33.7% YoY
LTMMar 2026
44.2M+35.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+111.5%——
1 year+33.7%——
3-year CAGR+39.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
42.22M USD
Year-over-year change
+33.7%
4-year CAGR
+17.2%

Weighted Avg Shares vs competitors

How PEPG compares with its peers on the latest reported figures

  • PEPG's LTM Mar 2026 weighted avg shares of 44.2M shares is the 5th highest of the 8 companies compared; the peer median is 67.15M shares.
  • Its year-over-year change of +35.7% is the highest of 8, against a peer median of +9.0%.
  • Over three fiscal years its annual growth of +39.2% compares with a peer median of +15.3%.
PEPG Competitors Peer median
Weighted Avg Shares for PEPG and competitors
Company Period LTM YoY 3-year CAGR
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
ALECAlector, Inc.LTM Mar 2026104.14M +6.5%+7.7%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
PEPGPepGen Inc.LTM Mar 202644.2M +35.7%+39.2%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
Peer median (excluding PEPG) 67.15M+9.0%+15.3%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.18M1.51M1.4M
Gross Profit00(1.18M)(1.51M)(1.4M)
Gross Margin—————
Research & Development23.8M54.08M68.13M76.48M71.04M
Selling, General & Admin8.11M14.22M16.64M21.26M22.57M
Operating Expenses27.11M68.3M83.58M96.23M92.22M
Depreciation & Amortization178K493K1.18M1.51M1.4M
EBITDA(27.1M)(64.91M)(77.37M)(89.09M)(88.21M)
EBITDA Margin—————
Operating Income(27.11M)(68.3M)(84.77M)(97.74M)(93.61M)
Operating Margin—————
Interest Income02.79M6.4M7.14M4.02M
Interest Expense00000
Other Income / Expenses(172K)2.9M6.21M7.14M4.01M
Income Before Tax(27.28M)(65.4M)(78.55M)(90.6M)(89.61M)
Pre-Tax Margin—————
Income Tax Expense03.71M73K(617K)49K
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Net Margin—————
EPS (Basic)(1.22)(4.42)(3.30)(2.85)(2.12)
EPS (Diluted)(1.22)(4.42)(3.30)(2.85)(2.12)
Weighted Avg Shares22.39M15.64M23.8M31.58M42.22M
Weighted Avg Shares (Diluted)22.39M15.64M23.8M31.58M42.22M

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.